|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
6
|
Resverlogix Corp.
|
Nov 02, 2020 06:41PM
|
|
Re: Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
|
5
|
Resverlogix Corp.
|
Nov 02, 2020 07:32PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
2
|
Resverlogix Corp.
|
Dec 07, 2017 02:16AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 10:35AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
3
|
Resverlogix Corp.
|
Dec 07, 2017 12:17PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
2
|
Resverlogix Corp.
|
Dec 07, 2017 01:02PM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
1
|
Resverlogix Corp.
|
Dec 07, 2017 08:12PM
|
|
Re: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
|
6
|
Resverlogix Corp.
|
Jan 11, 2018 01:23PM
|
|
Re: Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
|
2
|
Resverlogix Corp.
|
Jan 11, 2018 04:39PM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
4
|
Resverlogix Corp.
|
May 30, 2017 12:47PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
10
|
Resverlogix Corp.
|
Jun 22, 2020 12:02PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
6
|
Resverlogix Corp.
|
Jun 22, 2020 12:29PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:09PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
5
|
Resverlogix Corp.
|
Jun 22, 2020 08:46PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 09:00PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 23, 2020 02:22AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 23, 2020 02:26AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
4
|
Resverlogix Corp.
|
Aug 23, 2022 05:21PM
|
|
Re: Resverlogix Publications, Presentations and Abstracts
|
2
|
Resverlogix Corp.
|
Sep 27, 2017 10:19AM
|
|
Re: Resverlogix now listed as a Presenting Company at Biopharm America
|
2
|
Resverlogix Corp.
|
Sep 22, 2017 11:34AM
|
